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HTS and hit finding in academia – from
chemical genomics to drug discovery
Julie A. Frearson and Iain T. Collie
Drug Discovery Unit, Sir James Black Centre, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK
The liaison between academia and the pharmaceutical industry was originally served primarily through
the scientific literature and limited, specific industry–academia partnerships. Some of these partnerships
have resulted in drugs on the market, such as Vorinostat (Memorial Sloan-Kettering Cancer Centre and
Merck) and Tenofovir (University of Leuven; Institute of Organic Chemistry and Biochemistry, Czech
Republic; and GlaxoSmithKline), but the timescales from concept to clinic have, in most cases, taken
many decades. We now find ourselves in a world in which the edges between these sectors are more
blurred and the establishment and acceptance of high-throughput screening alongside the wider
concept of ‘hit discovery’ in academia provides one of the key platforms required to enable this sector to
contribute directly to addressing unmet medical need.Introduction
The days of a clear distinction between academia’s and industry’s
roles in developing new therapies are long gone and, in the past
ten years, a small revolution has taken place within institutions
previously recognized as centres of international excellence in
fundamental research. Many such institutions now have transla-
tional research-based groups and platforms developed to take basic
research and apply it towards clinical applications. Academia has
for some time recognized the role of identification of chemical
matter in the endeavour of addressing specific biological ques-
tions, and the stochastic nature of screening for these molecules is
now widely accepted as a legitimate discipline in this sector. There
are many academic contextualized screening centres across the
world, each with different specializations and remits and, collec-
tively, they represent a vast transfer of knowledge and technology
bases from industry into academia. The resulting blend of aca-
demic endeavour and innovation with industrial purpose and
discipline provides fertile grounds for translational research. It
is anticipated that the drive from funding bodies towards transla-
tional research will sustain these activities as they continue to
address chemical genomics and, increasingly, enter the world of
drug discovery. While the pharmaceutical sector has to moderate
its strategy to cope with challenging business and economic times,Corresponding author: Frearson, J.A. (j.a.frearson@dundee.ac.uk)
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a level of maturity and robustness with which it can contribute
meaningfully to the development of new mode-of-action thera-
pies against a range of diseases, not least neglected and niche
diseases. In this review, we aim to give an overview of the current
academic screening sector and provide opinions on areas for future
focus and development. We use the terms ‘academia’ and ‘aca-
demic’ to encompass both teaching and non-teaching institutes,
plus some other not-for-profit centres, and to distinguish them
from the traditionally recognized pharmaceutical and biotechnol-
ogy sectors.
Stakeholders in academic screening
In addition to the university system itself, there are several other
bodies that have important roles in funding, overseeing, translat-
ing and guiding the research and screening output in the academic
sector. Government-funded bodies, such as the Medical Research
Council (MRC) in the UK and the National Institutes for Health
(NIH) in the US, have always invested in leading-edge research
activities within universities and research institutes, but over the
past decade a noticeable focus on drug discovery initiatives and
screening facilities has been evident: for example, see the MRC’s
Translational Research Strategy [1] and the NIH Roadmap Initia-
tive [2]. Charitable and philanthropic funding is also a notable
source of support for the translational research sector, including/06  2009 Elsevier Ltd. doi:10.1016/j.drudis.2009.09.004Open access under CC BY license.
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BOX 1
A selection of some representative ‘academic’ screening
facilities
Drug Discovery Centre, London, UK
http://www1.imperial.ac.uk/medicine/research/institutes/
drugdiscoverycentre/
Remit: Translational biology for ICL discoveries.
Focus: Currently, cancer, anti-infectives, Alzheimer’s, inflammation,
anaesthesia and transplantation.
Medical Research Council Technology – Centre for Therapeutics
Discovery, London, UK
http://www.mrctechnology.org/CO_DD.htm
Remit: To translate MRC-funded scientific discoveries into commercial
products for healthcare benefit and to re-invest in future research.
Focus: Wide target range across broad therapeutic areas.
University of Dundee – Drug Discovery Unit, Dundee, UK
http://www.drugdiscovery.dundee.ac.uk/
Remit: Translational drug discovery for unmet medical needs and
neglected diseases.
Focus: Tropical diseases, novel targets and mechanisms, and stem cells.
Cancer Research Technology Discovery Laboratories, Cambridge
and London, UK
http://www.cancertechnology.com/pages/about_devlab_drugdisc.html
Remit: To translate CRUK-funded research into novel cancer therapies.
Focus: Broad target approach to drug discovery and biotherapeutic
development in cancer.
Cancer Research UK Centre for Cancer Therapeutics, London, UK
http://www.icr.ac.uk/research/research_sections/cancer_therapeutics/
index.shtml
Remit: To identify novel genes and pathways as targets and to implement
novel technologies.
Focus: HTS and high-content screening (HCS) including phenotypic
screening, and target families including kinases, ATPases, protein–protein
interactions and signalling pathways.
Drug Discovery Portal, Glasgow, UK
http://www.ddp.strath.ac.uk/index.php
Remit: Partnership drug discovery.
Focus: Virtual screening and structure- and ligand-based design.
MRC Centre for Developmental and Biomedical Genetics, Sheffield,
UK
http://cdbg.shef.ac.uk/
Remit: Generation of animal models of human disease using a translational
approach.
Focus: Developmental studies in zebrafish and drosophila.
European Molecular Biology Laboratory, Heidelberg, Germany
http://www.embl.de/services/core_facilities/chemcore/index.html
Remit: To open up screening opportunities to research groups within and
outside EMBL.
Focus: In the Chemical Biology Core Facility, to support academic
partners in primary and secondary assay development, screening and
chemical optimization.
European ScreeningPort, Hamburg, Germany
http://www.screeningport.com/
Remit: To offer fee-for-service screening to academic institutions.
Focus: Diverse target classes and therapeutic areas welcomed; utilize
industry-standard platform technologies.
Leibniz-Institut fu¨r Molekulare Pharmakologie, Berlin, Germany
http://www.fmp-berlin.de/index_e.html
Remit: Open-access platform for academic projects.
Focus: Fragment screening by NMR; ChemBioNet compound collection
repository.
E´cole Polytechnique Fe´de´rale de Lausanne – Biomolecular
Screening Facility, Basel, Switzerland
http://bsf.epfl.ch/
Remit: To provide access to EPFL researchers and affiliates to molecular
screening infrastructure, expertises and collections of molecules.
Focus: Cancer, neurobiology and infectious diseases.
University of Leuven – Centre for Drug Design and Discovery
(CD3), Leuven, Belgium
http://lrd.kuleuven.be/en/entrepreneur/collaboration/cd3/about.htm
Remit: To collaborate with academic research groups and small
companies on innovative targets or approaches.
Focus: Viral, bacterial and fungal diseases; central nervous system (CNS)
disorders and cancer.
Broad Institute, Cambridge, MA, USA
http://www.broad.mit.edu/
Remit: To capitalize on genome-related science and discoveries.
Focus: Chemical Biology Platform encompassing chemistry, informatics
and screening using HTS, HCS, phenotypic screens and RNAi screening.
NIH Chemical Genomics Center, Rockville, MD, USA
http://www.ncgc.nih.gov/
Remit: To provide a national resource in chemical probe development.
Focus: To develop chemical probe research tools relevant to physiology
and disease; includes online publicly available NCGC Assay Guidance
Manual.
Johns Hopkins University – ChemCORE Facility, Baltimore, MD, USA
http://www.hopkinschemcore.org/
Remit: To provide comprehensive compound screen services and
technology development.
Focus: Special expertise with ion channels, transporters and
G-protein-coupled receptors.
The Scripps Research Institute – Translational Research Institute,
Florida, USA
http://www.scripps.edu/florida/tri/
Remit: Advanced Technologies and Drug Discovery components to the
Translational Research Institute.
Focus: Broad-based discovery structure including HTS, proteomics, flow
cytometry, NMR, medicinal chemistry and informatics.
Harvard Medical School Screening Facility (ICCB Longwood),
Boston, MA, USA
http://iccb.med.harvard.edu/
Remit: To provide a staff-assisted screening model to internal and external
visiting researchers.
Focus: Small molecule, RNAi and siRNA screening services.
Memorial Sloan-Kettering Cancer Center – High-Throughput
Screening Core Facility, New York, NY, USA
http://www.mskcc.org/mskcc/html/52147.cfm
Remit: To provide cost-effective high-throughput screening facilities to
local investigators.
Focus: Primarily cancer, although all projects considered.
St Jude Children’s Research Hospital – Chemical Biology and
Therapeutics Department HTS Core Facility, Memphis, TN, USA
http://www.stjude.org/basicscience
Remit: To discover and develop novel chemical entities that increase
understanding of the pathophysiology of or function as therapeutic leads
for the treatment of catastrophic paediatric illnesses.
Focus: Primarily childhood cancers.
University of Kansas – High-Throughput Screening Laboratory,
Lawrence, KS, USA
http://www.hts.ku.edu/index.php
Remit: To provide screening capabilities both locally and nationally.
Focus: Small-molecule library screening; siRNA screening.
Southern Research Institute, Birmingham, AL, USA
http://www.southernresearch.org
Remit: Drug Discovery Research Team focussing on cancer, infectious
disease and neuroscience.
Focus: HTS using BSL3 pathogens; antiviral, antimicrobial and anticancer
screening.
University of British Columbia – Centre for Drug Research and
Development, Vancouver, Canada
http://www.cdrd.ca/facilities-expertise/drug-screening
Remit: To advance promising discoveries to a commercially attractive
stage and to build a collaborative research infrastructure.
Focus: Cancer, CNS, diabetes and infectious diseases.
McGill University Life Sciences Research Complex, Montreal, Canada
http://www.lifesciencescomplex.mcgill.ca/hts-hcs
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Remit: To facilitate the development of chemical biology programmes in
academic laboratories using a staff-assisted screening model.
Focus: HTS and HCS projects.
Walter and Eliza Hall Institute of Medical Research – WEHI
Biotechnology Centre HTCS Facility, Melbourne, Australia
http://www.biotechcentre.net.au/HTCS/htcs.html
Remit: Open-access screening facility.
Focus: Molecular-target and cell-based screening approach using
conventional technology platforms, including surface plasma resonance
technology.
Eskitis Institute for Cell and Molecular Therapies, Griffith
University, Brisbane, Australia
http://www.griffith.edu.au/science/eskitis-institute-cell-molecular-therapies
Remit: To investigate novel drug- and cell-based therapies for cancer,
infection, neglected diseases, neurodegenerative diseases and stem cell
biology.
Focus: The ‘NatureBank’ natural product resource, adult stem cell
biology, breast cancer and Parkinson’s disease.
Institut Pasteur Korea, Kwanggyo, South Korea
http://www.ip-korea.org/
Remit: To further the Institut Pasteur’s mission by applying Korean
technology and competence in areas of neglected diseases.
Focus: Infectious and chronic diseases, nanotechnology,
PhenomicScreenTM and high-throughput flow cytometry.
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Research UK’s drug discovery operations (the Institute of Cancer
Research Centre for Cancer Therapeutics, and Cancer Research
Technology) and the Broad Institute. Furthermore, public–private
partnerships also use academic screening centres to push forward
their drug discovery portfolios; for example, the Drugs for
Neglected Diseases Initiative in partnership with the Drug Dis-
covery Unit (DDU) at Dundee [4] and Medicines for Malaria
Venture working with the Broad Institute [5].
The Society of Biomolecular Sciences Reference Library [6]
currently lists 64 different institutes around the world in its Aca-
demic Screening Facility Directory; 59% of these are based in the
USA (Fig. 1). Rather than exist in isolation, some of these groups
have formed national networks to realize mutual benefits (e.g. the
US Molecular Library Screening Centres Network [7], the EuropeanFIGURE 1
Geographical distribution of the majority of existing academic screening
centres (data drawn primarily from the SBS Academic Screening Facilities
Directory at http://www.sbsonline.org/).
1152 www.drugdiscoverytoday.comChemBioNet [8] and the UK Drug Discovery Consortium [9]). Box
1 summarizes some representative examples of academic screen-
ing facilities found around the world. These groups each differ in
their remits, which strongly dictate the nature of the platforms
and technologies they have established. One area of the sector is
dominated by the need to provide fully flexible platforms to
capture the widest possible range of ‘biologies’, develop and
release probes into the scientific community and make all screen-
ing data open access. The provision to the community of single-
point screening data in the absence of exposure to the underlying
quality control data and predictable interference of data sets with
false positives, however, can undermine the utility of this worthy
intention. The NIH Chemical Genomics Centre (NCGC) has
addressed this through the development and validation of a
quantitative high-throughput screening (HTS) platform that pro-
vides concentration–effect data for all compounds tested, resulting
in data with sufficient richness to engender confidence in activity
and initial structure–activity relationships (SARs) for the browsing
scientist [10]. Other centres operate with a similar community-
based spirit but directed more towards the endeavour of drug
discovery for neglected diseases, in which the outputs are leads
and preclinical candidates for suitably positioned partners to
develop further. Such organizations, therefore, focus their tech-
nologies and platforms on serving the needs of screening in the
context of the disease-causing organisms and information sharing
within defined project teams and consortia. The DDU at Dundee
(Box 1) represents a case in point.
Primary technologies
Where once academic laboratories were devoid of the automation
instrumentation that was increasingly deployed in the pharma
and biotech sectors of the industry during the 1990s, many of the
academic screening centres (Box 1) are now equally well equipped
to conduct medium- and high-throughput screening activities
(Table 1). Several changes have encouraged these developments,
including the availability of commercial compound library sets,
price maturation of the automation instrumentation sector, de-
specialization of systems and software, and movement of a skills
base from industry to academia. Many of the screening centres
located in academia have been able to recruit industry-experi-
enced personnel into their groups and, hence, the establishment
and implementation of well-established screening technologies
have been facilitated to the point where learning curves are being
abridged.
The discipline of hit discovery is underpinned by a raft of
technology requirements including a plethora of assay formats:
liquid handling, automation, large data set management and
chemoinformatics (Fig. 2). The extent and nature of the infra-
structure required by each screening centre is driven by their area
of specialism and the size of their screening collections. These
typically vary between 50,000 and 300,000, with screens generally
being run in 384-well plate formats. It is common to find labora-
tories adopting a workstation approach with modular ‘islands’ of
automation rather than fully integrated robotic installations, with
the notable exception of the larger ultra-HTS initiatives engaging
in 1536-well plate densities. In particular, the NCGC have devel-
oped a 1536-based robotic platform to support their quantitative
HTS [11].
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TABLE 1
Examples of some of the disciplines, technologies and automation instrumentation listed onwebpages as available at one ormore of 26
academic screening facilities reviewed online
Disciplines Automated liquid handling instruments Detection technologies Plate readers
Atomic absorption spectroscopy Aquarius (Tecan) AlphaScreen Analyst (Molecular Devices)
Automated microscopy Biomek 3000 (Beckman) Calcium flux Acquest (Molecular Devices)
Computational chemistry Biomek NX (Beckman) Cellular imaging ArrayScan/ArrayScan VTI (Thermo)
Drug metabolism and
pharmacokinetics
Biomek FX (Beckman) Dynamic mass redistribution Bioimager Pathway 435 and 855
(Becton Dickinson)
Flow cytometry Bravo (Velocity 11) Fluorescence intensity Epic (Corning)
High-content screening CyBiWell (CyBio) Fluorescence polarization EnVision/EnVision Xcite (PerkinElmer)
High-throughput screening Evolution P3 (Tecan) Homogeneous
time-resolved fluorescence
(HTRF)
Evolution (Tecan)
Medium-throughput screening FlexDrop (PerkinElmer) Luminometry FlexStation 3 (Molecular Devices)
Medicinal chemistry Freedom EVO (Tecan) Microfluidic
separation-based assays
FLUOstar OPTIMA (BMG)
NMR screening Hummingbird (Digilab
Genomic Solutions)
Patch-clamp Genios Pro (Tecan)
Phenotypic screening JANUS (PerkinElmer) Radiometry ImageXpress Micro (Molecular Devices)
siRNA libraries Multidrop (Thermo) IN Cell 1000 (GE Healthcare)
Small-molecule libraries MultiPROBE II Plus (PerkinElmer) LabChip 3000 (Caliper)
Structural biology Pin tools (V & P Scientific) MicroBeta TriLux (PerkinElmer)
PlateMate 2x2 (Thermo) NEPHELOstar (BMG)
PlateMate Plus (Thermo) NOVOstar (BMG)
Precision 2000 (BioTek) PatchXpress (Molecular Devices)
TekBench (Hamilton) PHERAstar (BMG)
Vprep (Velocity 11) POLARstar (BMG)
WellMate (Thermo) Safire/Safire 2 (Tecan)
SpectraMax/M5 (Molecular Devices)
TopCount (PerkinElmer)
Victor 2/Victor 3 (PerkinElmer)
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biochemical assay options that use all of the well-established
photo-detection technologies (absorbance, luminescence, fluores-
cence intensity, time-resolved fluorescence, fluorescence polariza-
tion, fluorescence resonance energy transfer and time-resolved
fluorescence resonance energy transfer) underpinning both mole-
cular-target- and cell-based screening. These formats are often
supported by a range of detectors, from standard multi-modal
readers to laser scanning cytometry, ultra-fast charge-coupled-
device-based wide field imaging and ultimately confocal high-
content screening systems. Some centres support their specialist
interests with whole-organism screening in protozoan parasites
(DDU, Dundee) and model multicellular organisms, such as zebra-
fish [12], nematodes and fruit flies [13]. Target-family-based or
technology-based specialist centres also exist, including John
Hopkins University Ion Channel Centre [14], which specializes
in high-throughput label-free technologies, automated patch
clamping and atomic absorption spectroscopy, and the University
of New Mexico Centre for Molecular Discovery Capabilities [15],
where high-throughput flow cytometry is performed in 384-well
format.The importance of high stringency assay development in this
sector cannot be overestimated. This subject belies one of the main
cultural and operational distinctions between academic and
industry-trained scientists. The concept of developing biological
assays and systems with sufficient robustness to operate at scale for
screening and then with longevity to support chemical probe
development or drug discovery is the one that brings distinct
challenges when adapting assay concepts from research labora-
tories. In recognition of this, the NCGC, in collaboration with
investigators from Eli Lilly, have compiled an Assay Guidance
Manual [16] to encourage good practice among the wider scientific
community.
In the past, screening centres have tended to develop in isola-
tion from the associated technologies and capabilities required to
make their outputs of the highest value. The most effective groups
in the sector recognize the importance of stringent compound
management [17,18] and have fully integrated capabilities in
chemoinformatics, synthetic organic chemistry and/or medicinal
chemistry. Having closely coupled chemistry platforms in these
centres is a key component because they play a vital part in
informing the design and selection of compound libraries,www.drugdiscoverytoday.com 1153
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FIGURE 2
Representation of some key elements underpinning an effective screening facility, including (clockwise, from top left): example of a rectangular design
experiment to optimize biochemical assay parameters, as depicted using MODDE V8 software (Umetrics); 2D scatter plot depicted using Vortex software
(Dotmatics); plate representation of compound potency depicted using ActivityBase XE software (IDBS); chemical registration view using Register software
(Dotmatics); compound storage facilities (REMP); automated liquid handling instrumentation; single-field images of plated cultured embryonic stem cells stained
for a pluripotency marker (upper), leishmania promastigotes (left), ribbon diagram of Trypanosoma brucei pteridine reductase (centre), Xenopus XLK2 kidney cell in
mitosis (right), electron micrograph of T. brucei (lower); and a bioinformatics array plot of screens (x-axis) against compounds (y-axis) where compound potency is
displayed as a colour gradient from red (most active) to green (inactive).
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early SAR development and enabling the required dissemination
of data, be it internally to drug discovery project teams or exter-
nally through open-access mechanisms.
Where do the hits come from?
Lessons learned over several years have now produced the concept
of a healthy balance of options for the discovery of chemical
matter for biological systems involving high-quality (although
not necessarily high-throughput) screening of well-designed,
appropriately propertied and enriched small molecule compound
libraries, besides the use of alternate approaches, including natural
products and small molecular fragments.
Small molecules
Small-molecule-based high-throughput screening has had a che-
quered history, even within its ancestral home of industrial drug1154 www.drugdiscoverytoday.comdiscovery. Much of the controversy surrounding its effectiveness is
born out of other trends in the pharmaceutical sector that hap-
pened in parallel; notably, the advent of combinatorial chemistry
and the molecular genomic revolution. When all three major
events connected – the availability of millions of chemistries,
hundreds of new molecular targets and the systems to permit
large-scale cross-screening – the outcome was one of considerable
investment without the anticipated stream of new chemical enti-
ties progressing towards the clinic [19]. Despite this, there are now
examples of molecules in the clinic that originated from high-
throughput screens, including agents used in the treatment of HIV
infection (Maraviroc [20] and Viramune [21]).
Most academic centres focus on small-molecule screening, and
many have several compound collections (Fig. 3) incorporating
both diversity-based and gene-family or target-focussed com-
pound sets, applying them strategically to individual screening
campaigns. The content, design and scale of the small molecule
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FIGURE 3
Relative size of compound collections held in 44 of the academic screening
facilities (data drawn from the SBS Academic Screening Facilities Directory). R
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intended purpose. There might be more scope for molecular
weight distribution in libraries destined for chemical probe dis-
covery, but beyond that, the property restrictions for lead-like drug
discovery requirements also apply to chemical biology scenarios
[22]. The avoidance of structures with promiscuous inhibitor
tendencies, toxicophores, reactive moieties and intractable che-
mistries are relevant in both contexts. In addition, libraries
intended for drug discovery utility need to further adhere to a
restricted range of physicochemical properties necessary for both
parenteral or oral bioavailability and, perhaps, central nervous
system penetration [23,24]. The optimum size of the compound
collection required to maximize diversity and to provide sufficient
representation to provide early SAR from the screening exercise is a
subject of much debate. The desire to screen large sets is born from
the need to identify a broad range of hit series, a crucial point in
the competitive arena of industrial drug discovery. In academic
screening centres, the compound sets need to cover the appro-
priate biology space; as much chemistry space as possible and – if
chemistry resource is limited for the elaboration of the hits and,
thereby, validation of the emergent series – a good level of repre-
sentation around core scaffolds is required to provide information
on the most robust series. Academic centre libraries have, in the
majority, been collated from scratch and derived from commercial
sources, allowing a design element to influence their content [25].
When purchasing from commercial space, it is crucial to apply
property filters and cherry pick compounds for inclusion to avoid
unnecessary over-representation of scaffolds. The University of
Dundee’s analysis of >4 million commercially available structures
revealed only 300,000 that were appropriately propertied for
inclusion into a drug discovery library and, after core fragment
analysis, it was concluded that these 300,000 structures could be
adequately represented by 80,000–100,000 compounds. Example
compound selection criteria for some screening centres have been
published [26,27]. The NIH Molecular Libraries Initiative [28] is
undoubtedly the largest academic compound collection. It cur-
rently holds approximately 300,000 compounds that cover speci-
alty sets, natural products, targeted libraries and diversity sets. A
full comparative analysis of all libraries in centres described in Box
1 has not been undertaken. However, a small-scale assessment at
Dundee (R. Brenk, personal communication, details to be pub-lished elsewhere) of libraries from five different groups revealed a
large overlap at the core fragment level and minimal overlap at the
compound level.
Natural products
Many precedents have been set regarding the utility of natural
products as therapeutics, including lovastatin [29], derived from a
fungus, and paclitaxel [30], derived from tree bark. Modern day
drug discovery has moved away from this endeavour because of
the complexity of identifying, purifying and chemically optimiz-
ing the active components. Nevertheless, academia has long been
associated with the investigation of these entities, and academic
screening, in many respects, owes its origins to this field. Most
centres have a natural product ‘aspect’ to their compound collec-
tions, and these natural products might often be used when small-
molecule probes are not easily identified; some centres specialize
in this offering. The Eskitis Institute for Cell and Molecular Thera-
pies at the Griffith University in Brisbane has access to the ‘Nature
Bank’ (Queensland Compound Library), a bank of more than
250,000 compounds from plants and marine invertebrates ready
for drug trials. The Nature Bank has taken more than ten years to
assemble and comprises unique compound samples collected from
flora and fauna across Australia, parts of China and the remote
tropical forests of Papua New Guinea. The utility of the hit output
from these sets is highly dependent upon aligned natural product
chemistry and microbiology expertise [31].
Fragments
Fragment-based hit discovery offers new possibilities for academic
screening groups, providing the opportunity to probe large areas of
chemical space in small-scale screening campaigns with a tech-
nology that is now a proven method of hit identification in
industry (for a review, see Ref. [32]). The primary concept behind
fragment-based hit discovery is that chemical space can be more
efficiently probed by screening collections of small fragments
(<250 Da). The initial fragments can then be optimized efficiently,
in many cases, to give compounds with potencies superior to those
from small-molecule screens and that lie well within Lipinski’s
rules. The low initial affinities returned by these fragments neces-
sitate an increased repertoire of assay technologies to support
standard bioassay. Although visualization of key fragments in
X-ray-derived structures is still required to develop fragments into
small molecules with good potency, a range of additional biophy-
sical techniques to screen for fragment hits, such as surface plas-
mon resonance (SPR), isothermal titration calorimetry and
thermal shift, has made the area generally more accessible. The
development of a fragment approach to hit discovery is, in many
ways, highly amenable to the academic drug discovery setting, and
such groups can apply this technique to the difficult, high-risk
target types that should be characteristic of the sector. In parti-
cular, a wealth of opinion is now building to suggest that frag-
ment-based hits are the way forward for targeting protein–protein
interactions [33–36].
Focus for the future
When faced with industry colleagues, they often ask the question
of academic screening and drug discovery: ‘what are you doing
that is different?’ Overall, we should be engaging in projects andwww.drugdiscoverytoday.com 1155
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ities in industry; working on neglected disease is a case in point.
We might, on the whole, use the same battery of methodology and
approaches, but these will be applied to distinctive, early-stage
targets and mechanisms for which the tractability or druggability
has yet to be proven. These are the projects that offer the real
opportunity to provide new mode-of-action therapeutics for gen-
uine unmet need. This sector also has the freedom to develop new
drug discovery paradigms, seeking to change the well-trodden
paths and methods of drug discovery to open up new target classes,
new mechanisms of action, new cell models and, perhaps, one day
addressing the ultimate goal of strategic polypharmacology [37].
How can hit discovery and screening itself contribute to this raft of
potential innovations? Certainly, the primary focus for develop-
ment in recent years has been the drive for continued miniatur-
ization by the industry; however, this is likely to diminish because
many operations become more individual-project- and focussed-
compound-set-orientated [38]. Therefore, a new set of advances in
hit discovery are now required, focussing on efforts to identify and
validate new targets, support drug discovery against new mechan-
isms and improve the overall efficiency of hit selection. The
academic hit discovery sector, together with industry, can have
an active role in these ambitions.
It is currently estimated that all of the FDA-approved drugs
collectively address just 324 targets (of which 266 are human) [39].
Hit discovery, therefore, is ripe for innovation to produce the
screening platforms that can address the large repertoire of
undrugged targets. Cell-based screening has emerged as a more
physiological alternative to isolated target-based approaches, with
the advantage of not presuming which target on a particular
pathway will be best to target [40], yet its full adoption has been
hindered by robustness issues, difficulties in target deconvolution
[41] and the undercurrent of reluctance among medicinal che-
mists to deal with the potential for complex SARs in the emergent
chemical matter. Hit discovery in this sector should have the
confidence and freedom to tackle pathway-based assays that pro-
vide a repertoire of potential targets and intervention points for
chemical matter. This approach can contribute markedly to iden-
tifying the novel druggable mechanisms in disease-relevant path-
ways. In cases in which the pathway is well defined, the target is
overexpressed and the required deconvolved steps are available,
target identification and confirmation of cell-based screening hits
can be straightforward: however, further advances are required to
find a systematic, broadly applicable approach for hits with no a
priori knowledge of the target.
There are numerous targets and mechanisms that have already
established good validation in vitro but require progression to in
vivo disease models to further assess their therapeutic potential.
This is often hindered by the inability to identify or develop drug-
like chemical matter. Our ability to address these difficult targets
(e.g. protein–protein interactions and protein–RNA interactions)
can be improved by focussing on the development of suitable
alternative assay methodologies. For example, there is increasing
confidence that fragment-based approaches offer improved oppor-
tunities for screening against difficult targets, such as protein–
protein interactions, that standard biochemical HTS cannot offer
[42]. The continued development of biophysical technologies,
such as SPR, that can support measurement of low-affinity ligands,1156 www.drugdiscoverytoday.comperhaps at multiple sites on a binding partner without total
dependence on X-ray crystallography, will be vital to exploit
the druggability of this target class [43].
Drives to enhance the efficiency of hit triaging and progression
decisions will come from developments in many disciplines, not
least chemoinformatics applications. Whatever the nature of the
biological information at hit stage, its information content and
physiological relevance will be a major factor in the downstream
success of any compound series. The availability of human pri-
mary cells for screening in primary mode is very limited, but this
could be abridged through progress being made in in vitro human
stem cell culture, differentiation and re-programming. Advances
in this field are aimed at overcoming the esoteric, ill-defined
growth factor or serum component relevance and genetic-mod-
ification-based protocols historically associated with differentia-
tion protocols. Several academically based groups have been
identifying small molecules that could mimic these processes
(reviewed in Refs. [44,45]). Academic screening centres are now
developing high-throughout screening platforms [46] as part of a
more comprehensive attempt to identify small molecules to direct
differentiation of stem cells towards authentic, human-drug-dis-
covery-relevant cell models such as cardiomyocytes, hepatocytes
and pancreatic b-cells. The marriage of authentic human cell
systems with technologies that enable real-time analysis of multi-
ple cellular events will result in a worthwhile contribution towards
making more informed judgements in hit triaging. Advances in
high-throughput microscopy and image analysis have the poten-
tial to deliver these possibilities by promoting this application
from the realms of secondary screening into a new era of routine
primary screening [47,48]. The advances in label-free screening
technologies evident in industry in recent years [49–51] will be
increasingly adopted by academic screening centres as its instru-
mentation base matures. As a result of the collective ability of these
technologies to support screening of endogenous targets in cel-
lular systems and reveal mode-of-action information in both cell
and isolated target scenarios, these platforms will also support the
march of hit discovery towards improved physiological relevance
and better informed hit selection.
Innovation in academic screening and its contribution to drug
discovery will also come from the evolution of its operating
models. There is increasing evidence of pharmaceutical companies
wanting to marry their in-house cell models with chemical matter
developed in the academic sector, such as Eli Lilly’s open innova-
tion programme. A sign that a new era of collaboration might be
upon us comes from early indications that companies are now
considering sharing the riches of their corporate collections with
academic screening centres to further exploit their chemical mat-
ter in novel target systems and/or support neglected disease drug
discovery.
Concluding remarks
There are numerous areas of drug discovery in which academically
contextualized groups can provide a pre-competitive harbour for
the development and testing of new targets, methods and para-
digms that can be implemented one day to improve drug discovery
productivity. Applied research in this sector will no doubt lead to
validation of new targets and mechanisms, new lead matter, new
methodologies and production of trained staff. There are sceptics
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not equate to tangible outputs [52], but it is crucial to allow a new
sector such as this time to establish itself, diversify its approaches
and grow towards a crucial mass of activity. It is also strategically
important to ensure that as the academic drug discovery sector
develops, it remains operationally and culturally distinctive from
the pharmaceutical sector so that they can work in synergy rather
than in competition. As the pharmaceutical industry re-organizes
itself to respond to highly challenging times, the academic sector
is in a position to help underpin drug discovery research. In doing
so, it will no doubt emerge over the next decade as an ever more
credible and worthwhile partner for industry in the future dis-
covery of new medicines. The increasing potential of this indus-
try–academic liaison has been reviewed recently [53].
For universities considering hosting a screening centre, the
primary advice is to align these operations with the academic
strengths of the organization in question and to have chemistryembedded to enable the progression of projects in a meaningful
and timely manner. Besides having an important part to play in
target validation, screening centres have the potential and
opportunity to move away from the individual molecular-target
approach and embark upon novel target discovery through
strategically coupled phenotypic screening and target identifi-
cation platforms. This represents a clear opportunity for the
sector to distinguish itself from industry-led approaches and,
ultimately, to provide important new knowledge to feed into
both the scientific literature and future pharmaceutical industry
pipelines.
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